10/07/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 10/7/2020. This three-page fact sheet informs healthcare providers of the significant known and potential risks and benefits of the emergency use of the ePlex® Respiratory Pathogen Panel 2. The ePlex® Respiratory Pathogen Panel 2 is authorized for use with nasopharyngeal swab specimens collected from individuals suspected of respiratory viral infection consistent with COVID-19 by their healthcare provider. (PDF)
.png)
No hay comentarios:
Publicar un comentario